A survey by the Business Group on Health reveals that 68% of large employers now cover GLP-1 weight loss medications in their health plans, up from 41% in 2024. The rapid expansion is driven by employee demand and growing evidence of long-term health benefits.
Coverage varies significantly. Some employers cover the medications only for patients with BMI over 35 or those with obesity-related comorbidities, while others have adopted broader criteria. Annual per-patient costs of $12,000-15,000 are straining plan budgets, with some employers spending 5% of their total drug budget on GLP-1s alone.
To manage costs, employers are implementing step therapy requirements, mandatory lifestyle counseling, and partnerships with specialty pharmacies. Some are negotiating directly with manufacturers for volume discounts outside traditional pharmacy benefit channels.
The ROI case is emerging. Early data from employers who adopted coverage in 2024 shows reduced claims for diabetes, heart disease, and joint replacements among GLP-1 users. If sustained, these savings could offset the medication costs within 3-5 years.
Employers who don't cover the drugs face a competitive disadvantage in recruiting. Job seekers are increasingly asking about GLP-1 coverage during the benefits review process, making it a retention and recruitment factor.
